Liquidia Corporation $LQDA Shares Purchased by AWH Capital L.P.

AWH Capital L.P. raised its stake in Liquidia Corporation (NASDAQ:LQDA) by 8.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 92,500 shares of the company’s stock after buying an additional 7,500 shares during the period. Liquidia makes up approximately 2.9% of AWH Capital L.P.’s holdings, making the stock its 17th largest holding. AWH Capital L.P.’s holdings in Liquidia were worth $3,190,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after purchasing an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after acquiring an additional 16,022 shares during the last quarter. Creative Planning boosted its position in Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after acquiring an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in Liquidia by 13.4% during the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after acquiring an additional 11,111 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $68.65 on Thursday. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $73.22. The firm has a 50-day simple moving average of $51.76 and a 200 day simple moving average of $41.76. The company has a market cap of $6.11 billion, a PE ratio of 490.39 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, sell-side analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Insider Activity at Liquidia

In other news, Director Paul B. Manning sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the sale, the director directly owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. This represents a 21.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sanjeev Khindri sold 4,134 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $65.46, for a total transaction of $270,611.64. Following the completion of the sale, the insider directly owned 67,132 shares of the company’s stock, valued at approximately $4,394,460.72. This represents a 5.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 2,282,894 shares of company stock valued at $128,344,713. 25.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Wells Fargo & Company lifted their target price on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Oppenheimer set a $75.00 price target on shares of Liquidia in a research note on Friday, June 5th. Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).